Canada Lung Cancer Therapeutics Market By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)), By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments), By End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and By Region, Competition Forecast and Opportunities, 2018-2028
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationCanada Lung Cancer Therapeutics Market By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)), By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments), By End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and By Region, Competition Forecast and Opportunities, 2018-2028
According to the Canadian Cancer Society, an estimated 30,000 Canadians were diagnosed with lung and bronchus cancer, accounting for 13% of all new cancer cases in 2022. Moreover, 20,700 Canadians succumbed to lung and bronchus cancer, representing 24% of all cancer-related deaths in 2022.
Technological advancements
Technological advancements have played a significant role in influencing the growth of the Canada Lung Cancer Therapeutics Market. These advancements have revolutionized various aspects of lung cancer diagnosis, treatment, and research, leading to improved patient outcomes and expanded therapeutic options. Technological advancements have enabled the development of more accurate and efficient diagnostic tools for lung cancer. Imaging techniques, such as computed tomography (CT) scans and positron emission tomography (PET) scans, have become more sophisticated, allowing for earlier detection of lung tumors and improved staging of the disease. Additionally, molecular testing and biomarker analysis have facilitated the identification of specific genetic mutations and alterations in lung cancer cells, aiding in personalized treatment approaches.
Technological advancements have paved the way for precision medicine in lung cancer treatment. Genomic profiling techniques, such as next-generation sequencing (NGS), have become more accessible and cost-effective, enabling the identification of actionable mutations and biomarkers in lung cancer patients. This information guides the selection of targeted therapies, such as tyrosine kinase inhibitors (TKIs), which specifically block the activity of mutated genes or proteins driving tumor growth. These targeted therapies have shown remarkable efficacy and have transformed the treatment landscape for certain subsets of lung cancer patients.
Technological advancements have contributed to the development of immunotherapies for lung cancer. Immune checkpoint inhibitors, such as programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors, have demonstrated significant clinical benefit by harnessing the body's immune system to fight cancer cells. Advanced techniques for immune profiling, such as immune cell characterization and monitoring of immune response markers, help identify patients who are most likely to respond to immunotherapies and enable more precise treatment selection.
Growing emphasis on personalized medicine
The growing emphasis on personalized medicine has had a significant influence on the growth of the Canada Lung Cancer Therapeutics Market. Personalized medicine, also known as precision medicine, aims to tailor medical treatment to individual patients based on their specific characteristics, such as genetic makeup, biomarker profiles, and disease characteristics. In the context of lung cancer, personalized medicine has led to several advancements that have positively impacted the market's growth.
Personalized medicine has revolutionized the treatment of lung cancer by enabling the development of targeted therapies. Through molecular profiling and genetic testing, specific genetic mutations and alterations in lung cancer cells can be identified. This information helps identify patients who are most likely to benefit from targeted therapies, such as tyrosine kinase inhibitors (TKIs), that block the activity of mutated genes or proteins driving tumor growth. The availability and efficacy of targeted therapies have expanded treatment options, improved response rates, and prolonged survival for certain subsets of lung cancer patients.
Personalized medicine has placed significant emphasis on identifying biomarkers that predict treatment response and patient outcomes. Genetic testing, next-generation sequencing (NGS), and other advanced techniques have enabled the identification of specific biomarkers in lung cancer, such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and programmed death-ligand 1 (PD-L1) expression. These biomarkers help guide treatment decisions and assist in selecting the most appropriate therapies for individual patients. The identification and utilization of biomarkers have resulted in improved patient selection, increased treatment efficacy, and reduced adverse effects.
The growing emphasis on personalized medicine has spurred significant research and development (R&D) activities in the Canada Lung Cancer Therapeutics Market. Academic institutions, pharmaceutical companies, and research organizations are investing in the discovery and development of novel targeted therapies, immunotherapies, and treatment modalities that align with personalized medicine principles. The increased focus on personalized medicine has fueled collaborations and partnerships between researchers, clinicians, and industry stakeholders, driving innovation and the introduction of new therapeutic options.
Increasing research and developments efforts
Increasing research and development (R&D) efforts have a profound impact on the growth and advancement of the Canada Lung Cancer Therapeutics Market. Research and development activities drive innovation, foster scientific discoveries, and contribute to the development of novel therapies, treatment strategies, and diagnostic tools. R&D efforts in the field of lung cancer therapeutics lead to the discovery and development of novel therapeutic agents. Researchers investigate various molecular targets, signaling pathways, and cellular mechanisms involved in lung cancer progression, metastasis, and drug resistance. These efforts identify new potential targets for drug intervention, which can result in the development of innovative drugs, such as targeted therapies, immunotherapies, and combination therapies. The introduction of novel therapeutic agents expands the treatment options found at to patients, improves response rates, and enhances overall patient outcomes. Increasing research and development efforts contribute to advancements in treatment modalities for lung cancer. This includes the development of new treatment approaches beyond traditional chemotherapy and radiation therapy. For example, advancements in minimally invasive surgical techniques, such as video-assisted thoracic surgery (VATS), allow for more precise and less invasive tumor resections. Additionally, research in areas such as radiotherapy, stereotactic body radiation therapy (SBRT), and radiofrequency ablation (RFA) has improved the delivery and effectiveness of radiation-based treatments. These advancements enhance the overall treatment landscape and provide more options for lung cancer patients. Increasing research and development efforts contribute to the identification and understanding of biomarkers associated with lung cancer. Through extensive molecular profiling and genetic analysis, researchers identify specific genetic mutations, biomarkers, and other molecular characteristics that influence tumor behavior and treatment response. This knowledge enables personalized medicine approaches, guiding treatment decisions based on the unique genetic profile of each patient. Biomarker identification facilitates the selection of targeted therapies and immunotherapies, improving treatment efficacy and reducing unnecessary side effects.
Supportive regulatory environment
A supportive regulatory environment plays a crucial role in influencing the growth of the Canada Lung Cancer Therapeutics Market. Regulatory agencies and policies provide guidelines, standards, and oversight to ensure the safety, efficacy, and accessibility of lung cancer therapeutics. Regulatory agencies, such as Health Canada, may offer expedited approval pathways and fast-track designations for promising lung cancer therapies. These programs aim to accelerate the review and approval process for innovative treatments that address significant unmet medical needs. By expediting the regulatory timeline, these initiatives allow patients to access new therapies sooner, facilitating timely treatment and improving patient outcomes. A supportive regulatory environment provides clear and transparent guidance for conducting clinical trials in the field of lung cancer therapeutics. Regulatory agencies establish guidelines and requirements for trial design, patient selection, safety monitoring, and data collection. By offering comprehensive and standardized regulatory frameworks, these guidelines facilitate the planning and execution of clinical trials, ensuring their quality, reliability, and ethical conduct. Regulatory agencies foster collaboration and engagement with various stakeholders, including industry, healthcare professionals, patient advocacy groups, and academic institutions. This collaboration allows for the exchange of knowledge, insights, and expertise, promoting a shared understanding of the regulatory landscape and the evolving needs of lung cancer patients. Engaging stakeholders in the regulatory decision-making process helps ensure that regulations are effective, responsive, and aligned with patient-centric goals.
Collaborative efforts and partnerships
Collaborative efforts and partnerships play a pivotal role in influencing the growth of the Canada Lung Cancer Therapeutics Market. In a complex field like lung cancer, collaboration brings together the collective expertise, resources, and perspectives of various stakeholders, fostering innovation, driving research and development, and advancing patient care. Collaboration and partnerships facilitate the exchange of knowledge, ideas, and expertise among researchers, clinicians, academic institutions, pharmaceutical companies, and other industry stakeholders. By sharing insights, data, and best practices, these collaborations enable a more comprehensive understanding of lung cancer biology, treatment strategies, and emerging trends. This knowledge exchange accelerates scientific discoveries, promotes evidence-based practices, and enhances the quality of research and development efforts. Collaborative efforts foster advancements in R&D in the field of lung cancer therapeutics. By pooling resources, including funding, infrastructure, and technology, stakeholders can undertake larger and more ambitious research projects. Collaborative research initiatives can lead to the discovery of new therapeutic targets, the development of innovative treatments, and the identification of predictive biomarkers. Such advancements fuel the growth of the market by expanding treatment options, improving patient outcomes, and addressing unmet medical needs. Collaborative efforts promote the sharing and analysis of data in the field of lung cancer. Data pooling and collaborative research initiatives enable the integration of diverse datasets, including genomic information, clinical outcomes, treatment responses, and real-world evidence. By analyzing large and comprehensive datasets, researchers can identify trends, patterns, and potential correlations that would be otherwise difficult to observe in smaller datasets. This data-driven collaboration enhances the understanding of lung cancer, supports evidence-based decision-making, and facilitates the development of personalized treatment strategies.
Recent Developments
- Tagrisso is an oral medication developed by AstraZeneca and is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) with specific genetic mutations called epidermal growth factor receptor (EGFR) T790M mutations. It was approved by Health Canada in 2018.
- Keytruda is an immunotherapy drug developed by Merck, known as a PD-1 inhibitor. It is used for the treatment of advanced NSCLC, either as a first-line therapy in combination with chemotherapy or as a monotherapy for patients whose tumors express certain biomarkers. Keytruda received approval in Canada for lung cancer indications in 2019.
- Lorbrena, developed by Pfizer, is an oral medication indicated for the treatment of metastatic NSCLC with ALK-positive genetic mutations, including patients who have progressed on other ALK inhibitors. It was approved by Health Canada in 2020.
Market Segmentation
Market Players
AstraZeneca Canada Inc, Boehringer Ingelheim Canada Ltd, Bristol-Myers Squibb Canada Inc, Eli Lilly Canada Inc, Hoffmann-La Roche Ltd, Merck & Co Inc, Pfizer Canada Inc, Allergan Inc/Canada, Johnson & Johnson Inc/Canada are some of the leading players operating in the Canada Lung Cancer Therapeutics Market.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments Covered | By Cancer Cell Type By Treatment By End User By Region |
| Regional scope | Ontario region; Quebec region; Alberta region; British Columbia region; Saskatchewan and Manitoba region; Rest of Canada |
| Key companies profiled | AstraZeneca Canada Inc, Boehringer Ingelheim Canada Ltd, Bristol-Myers Squibb Canada Inc, Eli Lilly Canada Inc, Hoffmann-La Roche Ltd, Merck & Co Inc, Pfizer Canada Inc, Allergan Inc/Canada, Johnson & Johnson Inc/Canada |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy